schliessen

Filtern

 

Bibliotheken

Renal cell carcinoma

Considerable progress has been made in the treatment of patients with renal cell carcinoma, with innovative surgical and systemic strategies revolutionising the management of this disease. In localised disease, partial nephrectomy for small tumours and radical nephrectomy for large tumours continue... Full description

Journal Title: The Lancet 2009, Vol.373(9669), pp.1119-1132
Main Author: Rini, Brian I
Other Authors: Campbell, Steven C , Escudier, Bernard
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0140-6736 ; E-ISSN: 1474-547X ; DOI: 10.1016/S0140-6736(09)60229-4
Link: https://www.sciencedirect.com/science/article/pii/S0140673609602294
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_S0140_6736_09_60229_4
title: Renal cell carcinoma
format: Article
creator:
  • Rini, Brian I
  • Campbell, Steven C
  • Escudier, Bernard
subjects:
  • Medicine
ispartof: The Lancet, 2009, Vol.373(9669), pp.1119-1132
description: Considerable progress has been made in the treatment of patients with renal cell carcinoma, with innovative surgical and systemic strategies revolutionising the management of this disease. In localised disease, partial nephrectomy for small tumours and radical nephrectomy for large tumours continue to be the gold-standard treatments, with emphasis on approaches that have reduced invasiveness and preserve renal function. Additionally, cytoreductive nephrectomy is often indicated before the start of systemic treatment in patients with metastatic disease as part of integrated management strategy. The effectiveness of immunotherapy, although previously widely used for treatment of metastatic renal cell carcinoma, is still controversial, and is mainly reserved for patients with good prognostic factors. Development of treatments that have specific targets in relevant biological pathways has been the main advance in treatment. Targeted drugs, including inhibitors of the vascular endothelial...
language: eng
source:
identifier: ISSN: 0140-6736 ; E-ISSN: 1474-547X ; DOI: 10.1016/S0140-6736(09)60229-4
fulltext: fulltext
issn:
  • 0140-6736
  • 01406736
  • 1474-547X
  • 1474547X
url: Link


@attributes
ID362793789
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_S0140_6736_09_60229_4
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_S0140_6736_09_60229_4
sourcesystemPC
dbid
0--K
1--M
2.FO
31B1
41P~
51RT
6457
74G.
87-5
99JM
10AABNK
11AAEDT
12AAQFI
13ABBQC
14ABFNM
15ABMZM
16ABYKQ
17ACIUM
18ACRLP
19AEKER
20AEVXI
21AFKWA
22AFTJW
23AFXIZ
24AGHFR
25AHHHB
26AITUG
27AJBFU
28AJOXV
29AJRQY
30AJUYK
31AMFUW
32ANZVX
33BNPGV
34EO8
35EO9
36EP2
37EP3
38FDB
39FGOYB
40FIRID
41FNPLU
42G-Q
43GBLVA
44J1W
45KOM
46OD.
47OO~
48P-8
49P-9
50PC.
51R2-
52RPZ
53SAD
54SDF
55SDG
56SEL
57SES
58SSH
59SSZ
60T5K
61UV1
62Z5R
pqid67086842
galeid350515587
display
typearticle
titleRenal cell carcinoma
creatorRini, Brian I ; Campbell, Steven C ; Escudier, Bernard
ispartofThe Lancet, 2009, Vol.373(9669), pp.1119-1132
identifier
subjectMedicine
descriptionConsiderable progress has been made in the treatment of patients with renal cell carcinoma, with innovative surgical and systemic strategies revolutionising the management of this disease. In localised disease, partial nephrectomy for small tumours and radical nephrectomy for large tumours continue to be the gold-standard treatments, with emphasis on approaches that have reduced invasiveness and preserve renal function. Additionally, cytoreductive nephrectomy is often indicated before the start of systemic treatment in patients with metastatic disease as part of integrated management strategy. The effectiveness of immunotherapy, although previously widely used for treatment of metastatic renal cell carcinoma, is still controversial, and is mainly reserved for patients with good prognostic factors. Development of treatments that have specific targets in relevant biological pathways has been the main advance in treatment. Targeted drugs, including inhibitors of the vascular endothelial...
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0140673609602294$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Rini, Brian I
1Campbell, Steven C
2Escudier, Bernard
titleRenal cell carcinoma
description

Considerable progress has been made in the treatment of patients with renal cell carcinoma, with innovative surgical and systemic strategies revolutionising the management of this disease. In localised disease, partial nephrectomy for small tumours and radical nephrectomy for large tumours continue to be the gold-standard treatments, with emphasis on approaches that have reduced invasiveness and preserve renal function. Additionally, cytoreductive nephrectomy is often indicated before the start of systemic treatment in patients with metastatic disease as part of integrated management strategy. The effectiveness of immunotherapy, although previously widely used for treatment of metastatic renal cell carcinoma, is still controversial, and is mainly reserved for patients with good prognostic factors. Development of treatments that have specific targets in relevant biological pathways has been the main advance in treatment. Targeted drugs, including inhibitors of the vascular endothelial...

subjectMedicine
general
0English
1Elsevier Ltd
210.1016/S0140-6736(09)60229-4
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_S0140_6736_09_60229_4
issn
00140-6736
101406736
21474-547X
31474547X
rsrctypearticle
creationdate2009
addtitleThe Lancet
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
31B1
41P~
51RT
6457
74G.
87-5
99JM
10AABNK
11AAEDT
12AAQFI
13ABBQC
14ABFNM
15ABMZM
16ABYKQ
17ACIUM
18ACRLP
19AEKER
20AEVXI
21AFKWA
22AFTJW
23AFXIZ
24AGHFR
25AHHHB
26AITUG
27AJBFU
28AJOXV
29AJRQY
30AJUYK
31AMFUW
32ANZVX
33BNPGV
34EO8
35EO9
36EP2
37EP3
38FDB
39FGOYB
40FIRID
41FNPLU
42G-Q
43GBLVA
44J1W
45KOM
46OD.
47OO~
48P-8
49P-9
50PC.
51R2-
52RPZ
53SAD
54SDF
55SDG
56SEL
57SES
58SSH
59SSZ
60T5K
61UV1
62Z5R
startdate20090101
enddate20091231
lsr40The Lancet, 2009, Vol.373 (9669), pp.1119-1132
doi10.1016/S0140-6736(09)60229-4
citationpf 1119 pt 1132 vol 373 issue 9669
lsr30VSR-Enriched:[pqid, galeid]
sort
titleRenal cell carcinoma
authorRini, Brian I ; Campbell, Steven C ; Escudier, Bernard
creationdate20090000
lso0120090000
facets
frbrgroupid2920730514885085601
frbrtype5
newrecords20190904
languageeng
topicMedicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Rini, Brian I
1Campbell, Steven C
2Escudier, Bernard
jtitleLancet
creationdate2009
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Rini
1Campbell
2Escudier
aufirst
0Brian I
1Steven C
2Bernard
auinitB
auinit1B
au
0Rini, Brian I
1Campbell, Steven C
2Escudier, Bernard
atitleRenal cell carcinoma
jtitleThe Lancet
date2009
risdate2009
volume373
issue9669
spage1119
epage1132
pages1119-1132
issn0140-6736
eissn1474-547X
formatjournal
genrearticle
ristypeJOUR
abstract

Considerable progress has been made in the treatment of patients with renal cell carcinoma, with innovative surgical and systemic strategies revolutionising the management of this disease. In localised disease, partial nephrectomy for small tumours and radical nephrectomy for large tumours continue to be the gold-standard treatments, with emphasis on approaches that have reduced invasiveness and preserve renal function. Additionally, cytoreductive nephrectomy is often indicated before the start of systemic treatment in patients with metastatic disease as part of integrated management strategy. The effectiveness of immunotherapy, although previously widely used for treatment of metastatic renal cell carcinoma, is still controversial, and is mainly reserved for patients with good prognostic factors. Development of treatments that have specific targets in relevant biological pathways has been the main advance in treatment. Targeted drugs, including inhibitors of the vascular endothelial...

pubElsevier Ltd
doi10.1016/S0140-6736(09)60229-4
lad01The Lancet